TY - JOUR T1 - Using high <em>effective risk</em> of Adult-Senior duo in multigenerational homes to prioritize COVID-19 vaccination JF - medRxiv DO - 10.1101/2021.04.14.21255468 SP - 2021.04.14.21255468 AU - Brijesh Saraswat AU - Santosh Ansumali AU - Meher K. Prakash Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/14/2021.04.14.21255468.abstract N2 - Immediate and universal vaccination is a way of controlling the COVID-19 infections and deaths. Shortages of vaccine supplies and practical deployment rates on the field necessitate prioritization. The global strategy has been to prioritize those with a high personal risk due to their age or comorbidities and those who constitute the essential workforce of the society. Rather than a systematic age-based roll-down, assigning the next priority requires a local strategy based on the vaccine availability, the effectiveness of this specific vaccine, the population size as well as its age-demographics, the scenario of how the pandemic is likely to develop. The Adult (ages 20-60) – Senior (ages over 60) duo from a multigenerational home presents a high-risk demographic, with an estimated “effective age” of an adult to be 40 years more if they live with an unvaccinated grandparent. Our model suggests that strategically vaccinating the Adults from multigenerational homes in India may be effective in saving the lives of around 70,000 to 200,000 of Seniors, under the different epidemiological scenarios possible with or without strict lockdowns.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was available.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work is based on publicly available data. No ethics approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe work is based on publicly available data. The scripts will be made available on request. ER -